Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 26, 2015, 32 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $470.00 to $2,120,132.50.

Highlighted Stocks Traded by Insiders:

iGate (IGTE) - FREE Research Report

TST Recommends

Mcguinn Martin G, who is Director at iGate, sold 38,000 shares at $34.50 on Jan. 26, 2015. Following this transaction, the Director owned 57,425 shares meaning that the stake was reduced by 39.82% with the 38,000-share transaction.

Sircar Sujit, who is Chief Financial Officer at iGate, sold 4,358 shares at $32.58 on Jan. 26, 2015. Following this transaction, the Chief Financial Officer owned 145,142 shares meaning that the stake was reduced by 2.92% with the 4,358-share transaction.

The shares most recently traded at $34.13, up $1.55, or 4.54% since the insider transaction. Historical insider transactions for iGate go as follows:

  • 4-Week # shares sold: 10,073
  • 12-Week # shares sold: 10,073
  • 24-Week # shares sold: 10,073

The average volume for iGate has been 244,300 shares per day over the past 30 days. iGate has a market cap of $2.0 billion and is part of the technology sector and computer software & services industry. Shares are down 12.36% year-to-date as of the close of trading on Monday.

iGATE Corporation, through its subsidiaries, provides information technology (IT) and IT-enabled operations, and offshore outsourcing solutions and services to large and medium-size organizations. The company has a P/E ratio of 17.7. Currently, there are 8 analysts who rate iGate a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IGTE - FREE

TheStreet Quant Ratings

rates iGate as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, growth in earnings per share and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

iGate Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Horizon Pharma (HZNP) - FREE Research Report

Watkins Thomas, who is Director at Horizon Pharma, bought 6,000 shares at $9.76 on Jan. 26, 2015. Following this transaction, the Director owned 6,000 shares meaning that the stake was boosted by 100% with the 6,000-share transaction.

The shares most recently traded at $16.49, up $6.73, or 40.81% since the insider transaction. Historical insider transactions for Horizon Pharma go as follows:

  • 4-Week # shares sold: 64,201
  • 12-Week # shares sold: 64,201
  • 24-Week # shares sold: 64,201

The average volume for Horizon Pharma has been 1.8 million shares per day over the past 30 days. Horizon Pharma has a market cap of $1.9 billion and is part of the health care sector and drugs industry. Shares are up 27.54% year-to-date as of the close of trading on Monday.

Horizon Pharma plc, a specialty pharmaceutical company, through its subsidiaries, develops and commercializes medicines for the treatment of arthritis, pain, and inflammatory diseases. Currently, there are 6 analysts who rate Horizon Pharma a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on HZNP - FREE

TheStreet Quant Ratings

rates Horizon Pharma as a

sell

. The area that we feel has been the company's primary weakness has been its generally higher debt management risk. Get the full

Horizon Pharma Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

AZZ (AZZ) - FREE Research Report

Ferguson Thomas E, who is President and CEO at AZZ, bought 7,500 shares at $41.99 on Jan. 26, 2015. Following this transaction, the President and CEO owned 7,500 shares meaning that the stake was boosted by 100% with the 7,500-share transaction.

The shares most recently traded at $42.26, up $0.27, or 0.65% since the insider transaction. Historical insider transactions for AZZ go as follows:

  • 4-Week # shares bought: 2,000
  • 4-Week # shares sold: 1,000
  • 12-Week # shares bought: 2,000
  • 12-Week # shares sold: 1,000
  • 24-Week # shares bought: 2,929
  • 24-Week # shares sold: 7,798

The average volume for AZZ has been 131,800 shares per day over the past 30 days. AZZ has a market cap of $1.1 billion and is part of the industrial goods sector and industrial industry. Shares are down 8.99% year-to-date as of the close of trading on Monday.

AZZ incorporated manufactures electrical equipment and provides engineered services to power generation, transmission and distribution, and general industrial markets. The company operates through two segments, Electrical and Industrial Products and Services, and the Galvanizing Services. The stock currently has a dividend yield of 1.45%. The company has a P/E ratio of 18.1. Currently, there are 2 analysts who rate AZZ a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on AZZ - FREE

TheStreet Quant Ratings

rates AZZ as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, reasonable valuation levels, growth in earnings per share and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

AZZ Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null